Home>Topics>Companies>Dendreon Corporation

Dendreon Corporation

  1. All
  2. Commentary
  3. Headlines
  1. UPDATE 3-Valeant eyes smaller deals to build on Salix, Dendreon purchases

    Headlines

    Mon, 23 Feb 2015

    Feb 23 (Reuters) - Valeant Pharmaceuticals International Inc plans to strike smaller deals to build on its acquisitions of Salix Pharmaceuticals Ltd and assets of Dendreon Corp , its chief executive...

  2. REFILE-UPDATE 2-Valeant to buy bankrupt vaccine maker Dendreon

    Headlines

    Wed, 11 Feb 2015

    Feb 10 (Reuters) - Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp , after no additional qualified bids came forward by Tuesday's deadline, Valeant...

  3. UPDATE 2-Valeant to buy bankrupt vaccine maker Dendreon

    Headlines

    Tue, 10 Feb 2015

    Feb 10 (Reuters) - Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp , after no additional qualified bids came forward by Tuesday's deadline, Valeant said.

  4. Valeant appears poised to buy bankrupt vaccine maker Dendreon -sources

    Headlines

    Tue, 10 Feb 2015

    Feb 10 (Reuters) - Valeant Pharmaceuticals International Inc appears poised to scoop up bankrupt cancer vaccine maker Dendreon Corp after another potential buyer dropped from the bidding process,...

  5. Drugmaker Valeant raises bid for Dendreon cancer vaccine

    Headlines

    Thu, 5 Feb 2015

    Feb 5 (Reuters) - Valeant Pharmaceuticals International Inc said on Thursday it has raised its bid for worldwide rights to a prostate cancer vaccine owned by bankrupt drugmaker Dendreon Corp .

  6. UPDATE 1-Valeant to buy Dendreon's prostate cancer vaccine Provenge

    Headlines

    Thu, 29 Jan 2015

    Jan 29 (Reuters) - Bankrupt drugmaker Dendreon Corp has reached a stalking-horse deal with Canada's Valeant Pharmaceuticals International Inc to sell the worldwide rights to its cancer vaccine, Provenge , and certain assets for $296 million.

  7. Valeant to buy worldwide rights to Dendreon's Provenge

    Headlines

    Thu, 29 Jan 2015

    Jan 29 (Reuters) - Valeant Pharmaceuticals International Inc said it would buy the worldwide rights of Dendreon Corp 's Provenge drug and certain other assets through a "stalking horse" deal for $296...

  8. Dendreon Announces Chapter 11 Bankruptcy Filing; Discontinuing Coverage

    Commentary

    Thu, 20 Nov 2014

    cancer drug business. This news is not surprising, given the overhang from the $620 million in notes that were coming due in 2016, as the company continued to remain unprofitable despite Provenge sales of about $150 million last year.

  9. Dendreon Announces Chapter 11 Bankruptcy Filing; Placing Company Under Review

    Commentary

    Mon, 10 Nov 2014

    cancer drug business. This news is not surprising given the overhang from the $620 million in notes that were coming due in 2016, as the company continued to remain unprofitable despite Provenge sales of about $150 million last year.

  10. Second-Quarter Provenge Sales Are Solid; Convertible Debt Overhang Underscores Serious Risks

    Commentary

    Tue, 12 Aug 2014

    Dendreon reported second-quarter results ..... than our expectations, with solid Provenge sales. However, the ongoing lack ..... moat, negative trend ratings. Dendreon reported $82.2 million in Provenge sales for the quarter, a solid

« Prev1234Next »
Content Partners